LAUSR

Ovarian cancer (OC) is the seventh most commonly diagnosed cancer in world and the tenth most common in China (1). OC accounts for an estimated 239,000 annual new cases and 152,000 deaths worldwide (2). Although China has a relatively low incidence rate (4.1 per 100,000), the large population translated to an estimated 52,100 new cases and 22,500 related deaths in 2015 (3). Tradition treatment of OC has included surgery, during which doctors remove all visible tumors, chemotherapy, and radiotherapy (4). Advances in traditional cytotoxic chemotherapies, such as intraperitoneal administration and dose-dense therapeutic regimens, are improving response rates, as are novel target agents such as bevacizumab or poly (ADP-ribose) polymerase (PARP) inhibitors (5-7). However, these target agents have shown efficacy only in the early stages of some cases, and so more effective Original Article